Anemia in CKD is a common complication that has been reported in approximately 6 million people with CKD in the United States. Recent advancements in the understanding of the pathophysiology of CKD-associated anemia has led to the discovery of a new class of drugs, yet nephrologists may lack awareness of these therapeutic developments. Additionally, certain healthcare disparities may limit comprehensive management across the broader population of patients with anemia and CKD, consequently increasing the global burden of this complication. To ensure appropriate care and outcomes for patients, nephrologists require up-to-date education on the pathophysiology of anemia and CKD, burden of disease, current and emerging treatment options, and barriers to care.

The educational design of this activity addresses the needs of nephrologists and/or nephrology allied healthcare providers.